OcuHeal™ LNP

OcuHeal™ is a highly efficient eye-drop delivery mechanism to maximize drug delivery to deeper ocular tissues. We invite collaborations with pharmaceutical companies to render repurposed drugs IP-protectable with this  proprietary drug delivery licensable technology. With multiple billion-dollar drug products going off-patent, a 505(b)(2) regulatory strategy presents a cost-effective way to develop an extended product life cycle with novel IP. Contact us for a discussion.

90% Of All Commercial Eyedrops Are Highly Inefficient

The Problem

  • <95% of each eye drop is lost by naso-lacrimal drainage
  • Some critical eye medications are drug suspensions, not solutions
  • Drug suspensions lead to “graininess” on the ocular surface à feeling of “sand in the eye”
  • Higher drug concentrations needed for efficacyà leads to side effects and higher systemic drug presence
  • Issues of non-biocompatibility (pH, “sting”)

UnMet Clinical Need

  • Efficient, immediate drug absorption upon instillation of eye-drop
  • Optimized residence time of eye-drop
    • Optimize viscosity (enhance without causing blurred vision)
    • Optimize contact angle (minimize)
    • Optimize surface tension
  • Dissolved drug will enable immediate bioavailability
  • Immediate permeation of ocular mucosa into cornea

Introducing OcuHeal™ Lipid Nanoparticles

A highly efficient eye-drop delivery mechanism to maximize drug delivery to deeper ocular tissues

OcuHeal LNP
OcuHeal™ Drug Product becomes fluid at physiological temperature, slowly releasing drug from the nano-core matrix

OcuHealLipid Nanoparticles features

  • Rapid Tissue Penetration
  • Fully Dissolved Drug
  • Nanosized < 150 nm
  • Non-settling
  • Mucosa-Penetrating
  • Safe and Tolerable – OcuHealcontains excipients that are in approved ophthalmic medications.
  • Enabled technology for multiple drugs
  • Applicable to other routes

 

Fully Dissolved Drug, Nano-Sized, Non-aggregating, Preservative-Free, Non-Settling

Lipid Nanoparticles: Cryo-Transmission Electron Microscopy of OcuHeal™ Dispersion
Cryo-Transmission Electron Microscopy of OcuHeal™ Dispersion
100x oil immersion objective polarized light microscopy
100x oil immersion objective polarized light microscopy

Characteristics

Attribute

Fully Dissolved Drug

Yes

Particle Size Distribution (PSD)

D50 : < 200 nm

Stable

RT

Settling

Non-settling

Preservative

No preservative

Container closure

Multi-dose

Multi-Dose, Non-Settling, Non-Aggregating, Preservative-Free

multi-dose preservative-free bottle
Multidose Preservative-Free Bottle

Time

D10

(µm)

D50

(µm)

D90

(µm)

T=0

0.089

0.142

0.215

T=180d

0.086

0.138

0.209

T=360d

0.088

0.140

0.213

OcuHeal™ Patent Granted in Global Jurisdictions

Platform Delivery System: API- in- OcuHeal™Lipid Nanoparticles Eye-Drops Have a Flexible Composition of Lipid Excipients, Flexible Range of Sizes, Flexible Range of Lipid / Aqueous, Wide Portfolio of Drug Types, Scalable and Simple Manufacturing Process

  • Fully Patented
  • Technology applicable to multiple routes
  • Wholly owned by Symphony parent company, Integral BioSystems
  • Broad IP scope
  • Both Composition and Process IP
  • Patented in USA, Canada, Great Britain, France, Italy, Germany, Spain, India, Singapore, China, Japan, Australia, New Zealand, South Africa

OcuHeal™ products currently in co-development. Contact us today for a collaboration.